Climb Bio, Inc. (CLYM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Climb Bio, Inc. on December 11, 2025. The report details a material definitive agreement entered into on the same date with RA Capital Management, L.P. and an affiliated entity (the "Exchanging Stockholder").
Key Financial Metrics and Transaction Details
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or margins. The primary financial event reported is a share exchange transaction:
- Shares Exchanged: 20,440,000 shares of Common Stock.
- Instrument Issued: A pre-funded warrant to purchase 20,440,000 shares of Common Stock.
- Exercise Price: $0.0001 per share.
- Post-Transaction Outstanding Shares: 47,744,435 shares of Common Stock.
- Beneficial Ownership: RA Capital and affiliates will own approximately 23.0% of the outstanding voting power following the transaction.
Material Changes Versus Prior Period
The filing reports a structural change in the company's capitalization rather than operational performance changes. The transaction involves the retirement of 20,440,000 shares of common stock and their replacement with pre-funded warrants. This reduces the number of outstanding common shares while maintaining the economic exposure of the Exchanging Stockholder.
Guidance, Outlook, and Restrictions
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies beyond the transaction terms. Key contractual restrictions include:
- Voting Agreement: RA Capital and the Exchanging Stockholder agreed to vote any securities exceeding 33.0% of total voting power in proportion to the vote of all other stockholders.
- Ownership Cap: The Exchanging Holder cannot exercise the warrant if it would result in beneficial ownership exceeding 33.00% of outstanding shares, unless a notice is provided and a 61-day waiting period elapses to increase this threshold.
- Future Exchanges: RA Capital may exchange additional shares for pre-funded warrants subject to terms and company consent.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding (47,744,435) post-transaction to assess dilution or concentration of ownership.
- Confirm the 23.0% beneficial ownership stake held by RA Capital and affiliates.
- Review the 33.0% voting and exercise cap restrictions to understand potential limitations on future capital raises or share conversions.
- Note that the filing does not disclose the company's current cash position, burn rate, or liquidity status.